Knowledge

Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.

Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.

Follow us:

Publications

Insights

CMS Medicaid initiative allows states to limit drug coverage, keep manufacturer rebate obligations
Registered Content

On Jan. 30, 2020, the Centers for Medicare & Medicaid Services (CMS) announced the new Healthy Adult Opportunity (HAO) initiative through a State Medicaid Director letter, accompanied...

Insights

Senate Finance Committee Releases Details of Drug Pricing Bill Life Sciences & Health Care Alert
Registered Content

Yesterday, the Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-Oregon) released a description of The Prescription Drug Pricing Reduction Act of...

Hogan Lovells Publications

MDRP and the U.S. territories: Manufacturer rebate obligations, but no mandatory coverage, in case of a section 1115 waiver?

In the ACA Final Rule, the Centers for Medicare & Medicaid Service (CMS) expanded the definition of the terms “States” and “United States” for purposes of the...

Hogan Lovells Publications

340B program: CMP Final Rule effective and implementation date accelerated to January 1, 2019

Yesterday, the Health Resources and Services Administration (HRSA) issued a Final Rule (Final Rule) that accelerates the effective and implementation date of the 340B Ceiling Price and...

Analysis

Regulatory Insights for Life Sciences and Health Care Investments: Drug Pricing and Reimbursement
Registered Content

Investing in the life sciences industry without an understanding of the key regulatory factors that could determine a product's success or failure could cost you millions of dollars.

Hogan Lovells Publications

340B program: Proposed rule would accelerate the effective date of the CMP Final Rule from July 1, 2019, to January 1, 2019 Health Law

Yesterday, the Health Resources and Services Administration (HRSA) issued a Proposed Rule (Proposed Rule) to cease any further delay of the 340B Ceiling Price and Civil Monetary Penalties...

Hogan Lovells Publications

CMS considers linking Medicare drug payment rates to international prices Health Alert

On October 25, 2018, the Centers for Medicare & Medicaid Services (CMS) issued an advance notice of proposed rulemaking (ANPRM) describing a potential mandatory model to test Medicare...

Published Works

340B Program Restatements and Refunds: A whitepaper by Hogan Lovells and Deloitte Risk and Financial Advisory Published Works

It is a time of change in the 340B Program. Manufacturers should closely monitor 340B Program developments and prepare to respond promptly and effectively to changes in legal requirements....

Hogan Lovells Publications

Administration presents plans to lower drug prices Health Alert

On May 11, 2018, President Trump and Department of Health and Human Services (HHS) Secretary Alex Azar delivered highly anticipated speeches regarding the administration's plan to reduce...

Loading data